Natalizumab
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Natalizumab: From Multiple Sclerosis to Bronchitis
One-Sentence Summary
Natalizumab is a humanized monoclonal antibody against α4-integrin (VLA-4), publicly known to be used for relapsing multiple sclerosis and Crohn’s disease (original indication data was not captured in this evidence pack — see DG002). The TxGNN model’s top prediction is Bronchitis with a 99.46% score, but this candidate currently has 0 clinical trials and 0 publications supporting it, and the pack’s own mechanistic review flags it as likely unsupported.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in evidence pack (data gap — see DG002). Publicly known use: relapsing multiple sclerosis, Crohn’s disease |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.46% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data was not retrieved for this evidence pack (DG002, High severity). Based on the α4-integrin/VLA-4 pathway referenced in the pack’s own rationale text, natalizumab blocks lymphocyte adhesion and migration across endothelial barriers — a mechanism explored in airway inflammatory disease (e.g., asthma) but with no established treatment rationale for bronchitis.
The evidence pack’s own analysis for this candidate is explicit that the prediction is not well supported: bronchitis is predominantly infectious or irritant in etiology, blocking lymphocyte trafficking has no therapeutic rationale for it, and the resulting immunosuppression could plausibly increase infection risk. The pack flags this as a suspected knowledge-graph mis-connection through the respiratory/inflammation node cluster rather than a genuine mechanistic signal.
For context, the pack’s lower-ranked candidates (psoriasis, parapsoriasis, acute lichenoid pityriasis) are supported only by case-report literature in which natalizumab induces or aggravates dermatologic disease during MS treatment — the opposite therapeutic direction — with one isolated case report of comorbid psoriasis improving. None of the five ranked candidates in this pack currently have positive, disease-directed clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
Natalizumab is currently not marketed in the reference regulatory dataset (0 licenses/NDAs on record), so no authorization table can be produced.
Safety Considerations
Please refer to the package insert for safety information.
Note: this pack’s safety block (key warnings, contraindications, DDI) is fully a data gap (DG001, Blocking). Separately, literature surfaced while researching other ranked candidates (psoriasis) repeatedly documents progressive multifocal leukoencephalopathy (PML) as a serious class-level risk associated with natalizumab — this is not sourced from the formal safety fields but should be flagged for any follow-up safety review.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (bronchitis) has no clinical trial or literature support, and the pack’s own mechanistic review assesses it as an unsupported, likely spurious knowledge-graph link with a plausible risk of harm (immunosuppression in an infection-driven disease). None of the five ranked candidates in this pack show positive disease-directed evidence.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001, blocking — required before any S1 safety screen)
- Confirmed original indication and MOA documentation (DG002)
- Independent review of the TxGNN knowledge-graph edge for natalizumab–bronchitis to rule out node mis-linkage
- If the psoriasis signal is pursued instead, prospective controlled data — existing literature trends toward natalizumab causing/aggravating psoriasis, not treating it
- Regulatory pathway assessment, given the drug is not currently marketed (0 NDAs on record)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.